Evaluation of the eukaryotic expression of mtb32C-hbha fusion gene of Mycobacterium tuberculosis in Hepatocarcinoma cell line by تیمورپور, رقیه et al.
132
*Corresponding author: Zahra Meshkat (PhD), Antimi-
crobial Resistance Research Center, Mashhad University of 




Evaluation of the eukaryotic expression of mtb32C-hbha fusion gene of 
Mycobacterium tuberculosis in Hepatocarcinoma cell line  
Roghayeh Teimourpour1, Hosna Zare2, Ramazan Rajabnia3, Yousef Yahyapour3, Zahra Meshkat2*
 
1Department of Microbiology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
2Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
3Infectious Diseases & Tropical Medicine Research Center, Babol University of Medical Sciences, Babol, Iran
Received: October 2015, Accepted: January 2016
ABSTRACT 
 
Background and Objectives: HBHA and Mtb32C have been isolated from culture supernatants of Mycobacterium tu-
berculosis (M. tuberculosis) and Mycobacterium bovis (M. bovis) and their immunogenicity previously studies have been 
confirmed. In this study, capability of constructed vector containing two mycobacterial immunodaminant antigens (Mt-
b32C-HBHA), in producing new chimeric protein under the in-vitro condition was examined.
Materials and Methods: In present study Huh7.5 cells was transfected with Mtb32C-HBHA –pCDNA3.1+ recombinant 
vector using the calcium phosphate method and expression of chimeric protein was assessed by RT-PCR and Western blot 
methods.
Results: Results of RT-PCR and Western blot showed expression of 35.5 KD recombinant protein (Mtb32C-HBHA) in this 
cell line. 
Conclusion: The constructed vector can produce two highly immunogenic antigens that fusion of them to gather makes chi-
meric antigen with new traits. Other attempts are needed to evaluate specific properties of this new antigen such as molecular 
conformation modeling and immunologic characteristics in future studies.
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ganization (WHO) TB causes solely about 9 million 
annual deaths and 1.4 new cases in the world (3). Ba-
cillus Calmette–Guérin (BCG) vaccine can prevent 
disseminated forms of disease such as meningitis but 
unable to protect against  pulmonary tuberculosis 
and cannot be used in people with immunodeficien-
cy disorders. So the most important goal of WHO is 
to produce new effective vaccine to deal with this 
problem. Therefore, many efforts to develop an ef-
fective vaccine against tuberculosis are ongoing in 
the world (3-6).
One of the basic steps of the bacterial pathogen-
esis is the attachment of the microorganism to the 
host cells. Identifying adhesins involved in the early 
stages of the bacterial attachment and colonization 
followed by restricting these adhesins can prevent 














Tuberculosis (TB), is an infectious disease caused 
by Mycobacterium tuberculosis (1). This bacterium 
commonly enter from respiratory tract, involves lung 
and start to grow in alveolar macrophage however it 
can attack other parts of the body (2).
According to the latest reports of world health or-
http://ijm.tums.ac.ir
initiation and spread of infection to other sites.
In a study by Pethe et al. it was shown that the 
disruption of hbha gene in Mycobacterium tuber-
culosis or coating the wild type mycobacteria with 
anti- HBHA impaired the spread of infection from 
the nasal route to the spleen 
Therefore, these adhesins are suitable targets for 
vaccines or drugs design. HBHA in M. tuberculo-
sis is an adhesion binds to lung epithelial cells and 
plays a critical role in the spread of infection outside 
the lungs. Strains of M. tuberculosis lacking HBHA 
are not able to spread from lungs to other organs (7-
13).
Mtb32C is a C- terminal fragment of Mtb32A 
that encoded by Rv0125 gene. This gene presents 
only in several mycobacterial pathogens such as 
M. tuberculosis, M. leprae and M. bovis. Mtb32A is 
involved in pathogenicity and is a vaccine candidate 
especially its own C-terminal region (Mtb32C) (14-
18).
In the present study, ability of Mtb32C-HBHA re-
combinant vector in expressing of fused Mtb32C - 
HBHA gene was evaluated in Huh7.5 cell line
   
MATERIALS AND METHODS
 
   In previous study Mtb32C and HBHA genes isolat-
ed from M. tuberculosis H37Rv genome and cloned 
into pCDNA3.1+ vector (19). In current study its po-
tency to express chimeric Mtb32C-HBHA protein 
was tested.
Cell line and cell culture. Huh7.5 cell line was 
used to investigate the expression of mycobacterial 
antigens. It is an immortal cell line. Since this cell 
line is very stable and has a fast growth rate, it suits 
the studies aiming at evaluating the expression of fu-
sion proteins from recombinant vectors.
For transfection of cells, initially 104 of Huh7.5 cells 
cultured in 6 well plate (Invitrogen, USA) contain-
ing Dulbecco's modified Eagle's medium (DMEM) 
enriched with 10% fetal bovine serum (Invitrogen, 
USA), 0.2% sodium bicarbonate (Sigma, USA), 
100U/ml penicillin (Invitrogen, USA), and 100µg/
ml streptomycin (Invitrogen, USA) and incubated 
at 37°C and 5% CO2 until cell confluency reached 
to 70 %. Huh-7.5 cell line was transfected by calci-
um phosphate method as described previously (20); 
briefly, 5mg of the vector containing mycobacterial 
genes was diluted with 225μl double distilled water 
(DDW). Then, 25 μl of CaCl2 (2.5M) (21) was added 
until the final volume reached to 250 μl. Then, 250 
μ1 of HEPES buffer (274 mM NaCl, 10mM KCl, 1.4 
mM Na2HPO4, 15mM D-glucose, 42 mM HEPES at 
pH= 7.05-7.06) was added and final solution was kept 
for 20 -30 min at room temperature. At last stage, 
the obtained composition was added to Huh7.5 cell 
culture with 70% confluency. Four to six hours af-
ter transfection, old medium was replaced with fresh 
DMEM completed medium. Forty eight hours after 
transfection, transfected Huh7.5 cells along with un-
transfected cells as control were treated with trypsin 
enzyme (Invitrogen, USA) in order to recover cells 
(22).
RNA extraction. RNA was extracted from trans-
fected and untransfected Huh7.5 cells using RNX 
plus solution (CinnaGen, Iran) according to the man-
ufacturer’s protocols. In this way total RNA was 
obtained. To remove plasmid DNA, purified RNA 
was treated with DNase Ι (Fermentas, Germany) 
enzyme as described previously (23); Briefly, 3µg 
of RNA with 5 units of DNaseΙ enzyme and 10 X 
buffers in 10µl total volume prepared then incubated 
at 37 °C for 30 min. For inactivation of DNase Ι en-
zyme, mixture incubated at 65 °C for 10 min. More-
over, the  extracted RNA from transfected cells was 
examined for contamination with transfected re-
combinant plasmid by PCR method. Briefly, PCR 
reaction using specific primers for hbha and mtb32C 
genes was prepared and  extracted RNA  was used as 
template in the mixture. Negative results indicated 
absence of any plasmid contamination in RNA sam-
ples. 
The extracted RNA was then used for cDNA syn-
thesis and RT-PCR. 
cDNA synthesis and RT-PCR. In order to prepare 
cDNA for each sample, 5 µg of total RNA, 10pmol 
of oligo-dT primer, 3 µl DEPC-treated water mixed 
together and incubated the mixture at 65 °C for 5 min 
and chilled on ice and added to the mixture contain-
ing 5× RT buffer, 5 unit RNase inhibitor, 0.5 mM 
each dNTP, 5 unit thermo-resistance RT enzyme. 
The tubes were placed in thermal cycler (Applied 
Biosystem, USA) programmed as follows: (25 °C 10 
min, 47 °C 60 min ,70 °C 10 min). PCR reactions 
were prepared as follows: 2 µl of RT reaction, 2 µl 
of 10x PCR buffer, 2.5 mM MgCl2 , 0.1 mM each 
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dNTPs, 10 pmol of each primer specific for mtb32C 
gene fragment and 1 unit Taq DNA Polymerase. The 
PCR cycling program performed at initial denatur-
ation at 95 °C for 5min and then 35 cycles as fol-
lows: 95 °C for 60 seconds, 58 °C for 60 seconds, 
72 °C for 60 seconds followed by a final extension 
at 72 °C for 180 seconds. Finally, 5μl of the RT-PCR 
product was loaded on 1% agarose gel. A distinct ap-
proximately 400bp PCR product was visualized after 
Green Viewer staining (Pars Tous, Iran) in tranfected 
sample while in control sample and RNA samples no 
band was found.
Western blot analysis. Presence of recombinant 
protein was confirmed using Western blot analysis. 
To prepare samples, transfected cells and non-trans-
fected cells were harvested and washed with ice-
cold 0.5 ml phosphate buffer solution (PBS). Phenyl 
methyl sulfonyl fluorid protease inhibitor (PMSF) 
(Invitrogen, USA) was added at 1mM final con-
centration and then samples sonicated at 60Hz 
for 5 min, 2 times for releasing the proteins from 
cells. Determination of protein concentration was 
performed by Bradford assay. Loading buffer (4% 
SDS, 10% 2-mercaptoehtanol, 20% glycerol, 0.004% 
bromophenol blue, 0.125 M Tris HCl, pH 6.8 was 
added to each sample and boiled at 95-100 °C for 
5 minutes. Using sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE), 20 μg 
of protein was separated and then transferred to 
polyvinylidine difluoride (PVDF) (BioRad, USA) 
membrane in wet condition. In order to prevent any 
non-specific background binding, the membrane was 
blocked with blocker solution (5% (w/v) BSA, 0.5M 
NaCl, 0.02 M Tris pH= 8.5, 0.05% Tween 20) for 2 
hours at room temperature. Finally, the membrane 
stained with mouse anti-HisTag antibody (AbD Se-
rotec, UK) as primary antibody (1:1000 diluted in 
Tris-buffer saline-Tween (TBS-T) containing 50 mM 
Tris, 150 mM NaCl, 0.05% Tween 20, pH=7.6)  and 
peroxidase conjugated rabbit anti-mouse IgG anti-
body (AbD Serotec, UK) as secondary antibody ( 
1:1000 diluted in TBS-T). Expected band was detect-




Huh7.5 cell line was transfected with purified 
recombinant vector (Fig. 1) and expression of recom-
binant protein was confirmed by RT-PCR (Fig.M2).
Using calcium phosphate method, mycobacterial 
antigens successfully were expressed in Huh7.5 cell 




  Tuberculosis (TB) is a chronic disease that has 
Fig.1. Gel electrophoresis of the recombinant vector encod-
ing mtb32C-hbha fusion gene, after purification. Lanes 1 
and 2: purified recombinant vector containing mtb32C-hbha 
genes; lane3: 100bp DNA size marker (Fermentas, Germa-
ny)
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affected mankind for many years. Despite many at-
tempts TB remains a leading cause of death from a 
single agent of infection across the world and it is the 
first infectious disease announced by the World Health 
Organization (WHO) as international public health 
emergency. It is estimated that about 7% of all deaths 
in developing countries are contributed to TB (25-27).
  There are several ways to control TB such as im-
provement diagnostic methods, expansion and de-
velopment of new drugs and vaccines but most of 
researches in these areas were not successful. M. tu-
berculosis is easily transmitted by aerosol so the first 
host cells that encounter the bacteria are respiratory 
epithelial cells (13, 28). The result of the interaction 
between microorganisms with epithelial cells in the 
early stages of infection play an important role in the 
pathogenesis of bacterial infection and entering to the 
epithelial cells; therefore, effective immunity against 
adhesions can prevent bacterial colonization. Alveolar 
macrophages are the main target of the tubercle bacil-
lus, but the number of lung epithelial cells in this area 
is 500 to 1000 times higher than macrophages. There-
fore, much more likely these cells become infect-
ed than macrophages (29, 30). Evidence shows that 
mycobacterium can grow in epithelial cells and in in-
fected individuals bacteria can be isolated from these 
cells. These cells are important to spread the infection 
outside the lung. In this regard HBHA as bacterial ad-
hesion has significant role so that inactivation of this 
protein decline evasion of bacterium to the internal or-
gans such as spleen. Several studies have shown that 
HBHA recognized by T lymphocytes; leading to in-
duction of IFN-γ production in high-level thus HBHA 
is a proper vaccine candidate and is a good marker for 
differentiation of both normal individuals who have 
active tuberculosis from who are infected with M. tu-
berculosis (31-34).
    A gene encoding mtb32a is found in M. tuberculosis 
complex but absence in non- pathogenic and environ-
mental species. This gene is contributed to metabo-
lism of bacteria and cell survival. C-terminal fragment 
of Mtb32a (Mtb32C) can strongly motivate TCD8 
cells that produce IFN-γ and is a vaccine candidate. In 
previous study a DNA vaccine encoding Mtb32C and 
HBHA from M. tuberculosis was constructed and then 
its capacity in making protein investigated in current 
study (16, 35, 36).
   Not more than a decade has passed since the intro-
duction of the DNA vaccine. DNA vaccine  is a simple 
method for introducing antigens to the host that  the 
Fig. 2 Identification of Mtb32C mRNA in transfected and 
non-transfected Huh-7.5 cells by RT-PCR method. A 400bp 
fragment was amplified by RT-PCR method in transfected 
cells (lane 2); no amplification was resulted by RT-PCR on 
extracted RNA treated with DNase Ι (lane 3) and on synthe-
sized cDNA of non transfected cells (lane 4). Lanes 1 and 5: 
100bp DNA size marker (Fermentas, Germany)
Fig. 3. Recognition of an approximately 35.5 kDa band cor-
responding to Mtb32C-HBHA fusion protein in transfected 
cells (Lane 2) but not in non-transfected cells (Lane 1) by 
Western blot method
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first time was presented by Wolf (37). The DNA plas-
mid enter directly into the cells where transcription 
and translation genes of interest occur (27). In 1992 
Tang and colleagues demonstrated that plasmid DNA 
can lead to the stimulation of the host's immune sys-
tem (38). Next year the first report on the impact of 
protective role of DNA vaccine against infectious dis-
eases such as influenza was announced by Ulmer et al. 
(39). DNA vaccines have several important advantag-
es to other vaccines such as easy preparation, stability, 
low cost and safety for people with weakened immune 
systems. Nowadays DNA vaccine for cancer and ma-
laria are on the clinical stages and promising strategy 
to develop novel vaccine and drug (40, 41).
   In this study calcium phosphate method was used 
for transfection of Huh7.5 cells. In this method DNA 
can be introduced into wide variety of cell types via 
calcium phosphate co-precipitation(24).
DNA vaccine is quite a straightforward and efficient 
way for the stimulation of humoral and cellular im-
mune responses. In previous studies, the efficiency of 
mycobacterial DNA vaccines in small rodents have 
been confirmed (42). 
  DNA vaccines have several advantages over other 
types of vaccines. Among the advantages are the rel-
atively simple and cost-effective procedure of their 
production. This would result in the production of 
millions of doses of vaccines in a short time. Also, the 
vaccine is highly stable and does not require refriger-
ation chains. DNA vaccine is able to simultaneously 
stimulate the TCD8 + and Th1 CD4+ cells as well as 
the production of long lasting antibodies. Silva and 
Lowrie firstly reported that the DNA vaccine encoding 
Hsp 65 gene can stimulate protective responses and 
prevent the spread of tuberculosis in mice (42).
  The disadvantage of DNA vaccine is its low immu-
nogenicity. In order to enhance DNA vaccine immu-
nogenicity, extensive studies have been conducted 
such as the usage of genes related to stimulatory mol-
ecules, cytokines and using different routes for vac-
cine administration. Among these efforts are the injec-
tion of DNA vaccine along with CPG as an adjuvant 
which leads to the differentiation and proliferation of 
B Cells, NK Cells, monocytes, macrophages and lym-
phocytes (43).
  Recently, the prime-boost strategy has been em-
ployed to increase the efficiency of the DNA vaccine. 
In this method, the DNA vaccine has been adminis-
tered along with an alternative antigen. This alterna-
tive antigen can be a subunit protein, a recombinant 
viral vector such as adenovirus or inactivated micro-
organisms. This strategy is very effective in increasing 
the immunogenicity compared to cases in which the 
vaccine is administered alone (43). 
  Today, 15 years have passed after the first DNA 
vaccine entered the clinical trial studies but still no 
TB- specific DNA vaccine in humans have been 
commercialized. Nevertheless, many researchers are 
working on methods such as optimization of codons, 
recognition of the proper antigens, identification of in-
nate immune signaling molecules and using them as 
adjuvants, and using prime-boost strategy to increase 
the quality of DNA vaccines (44).The present work 
was successful in expression of recombinant Mt-
b32C-HBHA in Huh7.5 cell line and for confirming of 
expression in eukaryotic cells, RNA extraction, cDNA 
synthesis, RT-PCR and Western blot were used.
  In conclusion, the prepared vector efficiently can 
multiply in Huh7.5 cell culture system and produce 
protein. This construction can be used in another study 
for evaluation the immunological responses in animal 
model.
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